vs

Side-by-side financial comparison of PHOTRONICS INC (PLAB) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.

PHOTRONICS INC is the larger business by last-quarter revenue ($210.4M vs $158.6M, roughly 1.3× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 10.9%, a 60.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -5.5%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $25.2M).

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

PLAB vs STOK — Head-to-Head

Bigger by revenue
PLAB
PLAB
1.3× larger
PLAB
$210.4M
$158.6M
STOK
Growing faster (revenue YoY)
STOK
STOK
+3666.6% gap
STOK
3661.1%
-5.5%
PLAB
Higher net margin
STOK
STOK
60.3% more per $
STOK
71.2%
10.9%
PLAB
More free cash flow
STOK
STOK
$106.5M more FCF
STOK
$131.7M
$25.2M
PLAB

Income Statement — Q3 FY2025 vs Q1 FY2025

Metric
PLAB
PLAB
STOK
STOK
Revenue
$210.4M
$158.6M
Net Profit
$22.9M
$112.9M
Gross Margin
33.7%
Operating Margin
22.9%
70.2%
Net Margin
10.9%
71.2%
Revenue YoY
-5.5%
3661.1%
Net Profit YoY
-32.4%
528.0%
EPS (diluted)
$0.39
$1.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLAB
PLAB
STOK
STOK
Q3 25
$210.4M
Q2 25
$211.0M
Q1 25
$212.1M
$158.6M
Q4 24
$222.6M
$22.6M
Q3 24
$211.0M
Q2 24
$217.0M
Q1 24
$216.3M
Q4 23
$227.5M
Net Profit
PLAB
PLAB
STOK
STOK
Q3 25
$22.9M
Q2 25
$8.9M
Q1 25
$42.9M
$112.9M
Q4 24
$33.9M
$-10.5M
Q3 24
$34.4M
Q2 24
$36.3M
Q1 24
$26.2M
Q4 23
$44.6M
Gross Margin
PLAB
PLAB
STOK
STOK
Q3 25
33.7%
Q2 25
36.9%
Q1 25
35.6%
Q4 24
37.0%
Q3 24
35.6%
Q2 24
36.5%
Q1 24
36.6%
Q4 23
37.3%
Operating Margin
PLAB
PLAB
STOK
STOK
Q3 25
22.9%
Q2 25
26.4%
Q1 25
24.6%
70.2%
Q4 24
25.1%
-60.4%
Q3 24
24.7%
Q2 24
25.8%
Q1 24
26.6%
Q4 23
28.5%
Net Margin
PLAB
PLAB
STOK
STOK
Q3 25
10.9%
Q2 25
4.2%
Q1 25
20.2%
71.2%
Q4 24
15.2%
-46.4%
Q3 24
16.3%
Q2 24
16.7%
Q1 24
12.1%
Q4 23
19.6%
EPS (diluted)
PLAB
PLAB
STOK
STOK
Q3 25
$0.39
Q2 25
$0.15
Q1 25
$0.68
$1.90
Q4 24
$0.54
$-0.15
Q3 24
$0.55
Q2 24
$0.58
Q1 24
$0.42
Q4 23
$0.71

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLAB
PLAB
STOK
STOK
Cash + ST InvestmentsLiquidity on hand
$575.8M
$274.8M
Total DebtLower is stronger
$16.0K
Stockholders' EquityBook value
$1.1B
$350.1M
Total Assets
$1.8B
$406.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLAB
PLAB
STOK
STOK
Q3 25
$575.8M
Q2 25
$558.4M
Q1 25
$642.2M
$274.8M
Q4 24
$640.7M
$128.0M
Q3 24
$606.4M
Q2 24
$559.9M
Q1 24
$521.5M
Q4 23
$512.2M
Total Debt
PLAB
PLAB
STOK
STOK
Q3 25
$16.0K
Q2 25
$19.0K
Q1 25
$21.0K
Q4 24
$25.0K
Q3 24
$28.0K
Q2 24
$2.5M
Q1 24
$2.7M
Q4 23
$18.0M
Stockholders' Equity
PLAB
PLAB
STOK
STOK
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
$350.1M
Q4 24
$1.1B
$229.0M
Q3 24
$1.1B
Q2 24
$1.0B
Q1 24
$1.0B
Q4 23
$975.0M
Total Assets
PLAB
PLAB
STOK
STOK
Q3 25
$1.8B
Q2 25
$1.7B
Q1 25
$1.7B
$406.9M
Q4 24
$1.7B
$271.6M
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.6B
Q4 23
$1.5B
Debt / Equity
PLAB
PLAB
STOK
STOK
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×
Q4 23
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLAB
PLAB
STOK
STOK
Operating Cash FlowLast quarter
$50.1M
$131.8M
Free Cash FlowOCF − Capex
$25.2M
$131.7M
FCF MarginFCF / Revenue
12.0%
83.0%
Capex IntensityCapex / Revenue
11.8%
0.1%
Cash ConversionOCF / Net Profit
2.19×
1.17×
TTM Free Cash FlowTrailing 4 quarters
$64.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLAB
PLAB
STOK
STOK
Q3 25
$50.1M
Q2 25
$31.5M
Q1 25
$78.5M
$131.8M
Q4 24
$68.4M
$-23.2M
Q3 24
$75.1M
Q2 24
$76.5M
Q1 24
$41.5M
Q4 23
$106.6M
Free Cash Flow
PLAB
PLAB
STOK
STOK
Q3 25
$25.2M
Q2 25
$-29.1M
Q1 25
$43.3M
$131.7M
Q4 24
$25.2M
$-23.2M
Q3 24
$50.7M
Q2 24
$56.5M
Q1 24
$-1.8M
Q4 23
$54.1M
FCF Margin
PLAB
PLAB
STOK
STOK
Q3 25
12.0%
Q2 25
-13.8%
Q1 25
20.4%
83.0%
Q4 24
11.3%
-102.7%
Q3 24
24.0%
Q2 24
26.0%
Q1 24
-0.8%
Q4 23
23.8%
Capex Intensity
PLAB
PLAB
STOK
STOK
Q3 25
11.8%
Q2 25
28.7%
Q1 25
16.6%
0.1%
Q4 24
19.4%
0.2%
Q3 24
11.6%
Q2 24
9.2%
Q1 24
20.0%
Q4 23
23.1%
Cash Conversion
PLAB
PLAB
STOK
STOK
Q3 25
2.19×
Q2 25
3.55×
Q1 25
1.83×
1.17×
Q4 24
2.02×
Q3 24
2.18×
Q2 24
2.11×
Q1 24
1.59×
Q4 23
2.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

STOK
STOK

Segment breakdown not available.

Related Comparisons